NCT05233033View on ClinicalTrials.gov

Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

June 13, 2022

Primary Completion Date

July 28, 2023

Study Completion Date

July 28, 2023

Conditions
Non Hodgkin LymphomaDiffuse Large B Cell LymphomaDLBCLMYD88 Gene Mutation
Interventions
DRUG

KT-413

KT-413 will be supplied as 10mg/mL concentration frozen solution to be administered intravenously per the protocol defined dose level.

Trial Locations (8)

10065

Memorial Sloan Kettering Cancer Center, New York

20007

MedStar Georgetown University Hospital, Washington D.C.

22903

University of Virginia Comprehensive Cancer Center, Charlottesville

40207

Norton Cancer Institute, Louisville

48202

Henry Ford Health System, Detroit

77030

MD Anderson Cancer Center, Houston

Unknown

University College London Hospitals, London

University Hospital Southampton NHS Foundation Trust, Southampton

Sponsors
All Listed Sponsors
lead

Kymera Therapeutics, Inc.

INDUSTRY

NCT05233033 - Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL | Biotech Hunter | Biotech Hunter